$GH

Monroe Terilyn J. sold $7.6M of GH

Monroe Terilyn J. (Chief People Officer) sold 46,300 shares of Guardant Health, Inc. (GH) at an average of $165.12 ($163.41–$167.92, $7.65M total) across 5 trades on 2026-08-12.

Original reporting
SEC EDGAR · Monroe Terilyn J.
Published Aug 13, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 46,300 shares across five trades at an average price of about $165.12, totaling about $7.65M, with holdings after the sale of 22,979 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change Guardant’s fundamentals.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; without additional context, the signal is weak.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, trades executed 2026-08-12

Background

This is an SEC Form 4 insider transaction for Guardant Health, Inc. (GH) by Chief People Officer Monroe Terilyn J.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health insider Monroe Terilyn J. sold about $7.65M of GH shares in open-market trades on 2026-08-12.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the article provides transaction size and timing but no accompanying company news or guidance change.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted by some traders as higher signaling risk, potentially increasing short-term sensitivity to further insider activity.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an insider in the reported Form 4.

  • Monroe Terilyn J.

    Chief People Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

$GHHighAI 9/10

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for advanced HR-positive, HER2-negative breast cancer. This is the first FDA-approved liquid biopsy for longitudinal ctDNA testing in breast cancer. The approval was supported by clinical trial data showing early detection of ESR1 mutations. The company focuses on precision oncology, using blood and tissue tests to tailor cancer treatments. Investors should monitor the impact on future reve

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.